Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. News
  7. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

China approves Shanghai Fosun's unit to run human testing for BioNTech's COVID-19 vaccine

11/13/2020 | 06:28am EDT
Booth of Fosun Pharma is seen at a medical instruments and equipment expo in Beijing

HONG KONG/BEIJING (Reuters) - Shanghai Fosun Pharmaceutical Group said on Friday that its unit has received clinical trial approval from China's National Medical Products Administration for a COVID-19 vaccine candidate developed by German firm BioNTech.

The experimental COVID-19 vaccine, BNT162b2, is more than 90% effective based on initial results from large trials outside China, BioNTech's partner Pfizer Inc said on Monday.

Shanghai Fosun said in a company filing that its unit will begin a Phase II clinical trial in China for the candidate when the conditions are ready.

(Reporting by Twinnie Siu and Roxanne Liu. Editing by Jane Merriman)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 5.04% 328.35 Delayed Quote.283.45%
PFIZER, INC. 0.05% 42.81 Delayed Quote.16.25%
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. 9.54% 81.88 End-of-day quote.51.66%
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
07/28SHANGHAI FOSUN PHARMACEUTICAL : An announcement has just been published by the i..
PU
07/19Sisram Medical Seeks $80 Million in Private Placement; Shares Fall 6%
MT
07/19SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement entering into the placing..
PU
07/19SHANGHAI FOSUN PHARMACEUTICAL (GROUP : Ex-dividend day for final dividend
FA
07/14SINOVAC BIOTECH : Fosun-BioNTech COVID-19 vaccine completes China regulator revi..
RE
07/14MARKET CHATTER : BioNTech's COVID-19 Vaccine Advances to Administration Review i..
MT
07/14SHANGHAI FOSUN PHARMACEUTICAL : Poll results of the resolution proposed at the 2..
PU
07/13Hong Kong says no personal data shared in vaccine deal with Fosun
RE
07/13Sisram Medical Limited completed the acquisition of Shanghai Foshion Medical ..
CI
07/12Politics, health collided in Taiwan's tortured BioNTech vaccine talks
RE
More news
Financials
Sales 2021 40 257 M 6 231 M 6 231 M
Net income 2021 4 253 M 658 M 658 M
Net Debt 2021 15 917 M 2 464 M 2 464 M
P/E ratio 2021 48,3x
Yield 2021 0,64%
Capitalization 197 B 30 531 M 30 535 M
EV / Sales 2021 5,30x
EV / Sales 2022 4,69x
Nbr of Employees 32 258
Free-Float 58,8%
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | 600196 | CNE000000X38 | MarketScreener
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 81,88 CNY
Average target price 57,08 CNY
Spread / Average Target -30,3%
EPS Revisions
Managers and Directors
Xiao Hui Guan Executive President & Chief Financial Officer
Yu Qing Chen Co-President
Ke Xin Wang Co-President
Dong Ming Li Co-President
Yi Fang Wu Chairman